폴리, 캐슬 바이오사이언스 인수에서 알테아Dx 대리

폴리 앤 라드너 LLP는 오늘 정신건강 진단 기업인 알테아디엑스(AltheaDx, Inc.)가 환자 치료를 안내하는 혁신적인 검사를 통해 건강을 개선하는 캐슬 바이오사이언스(Castle Biosciences, Inc.)에 최근 인수된 과정에서 알테아디엑스를 대리했다고 발표했습니다.

AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that are focused on mental health. IDgenetix is its PGx test for depression, anxiety, and other mental health conditions.

Castle Biosciences acquired AltheaDx for initial consideration of $65 million, consisting of $32.5 million in cash, subject to adjustments for cash, debt, expenses and working capital, and $32.5 million in common stock of Castle Biosciences. There will be up to another $75 million in cash and common stock upon the achievement of certain milestones in fiscal years 2022 through 2024 and certain expansions of Medicare coverage of IDgenetix.

The Foley team representing AltheaDx was led by Partner Brandee Diamond and included Partners Belinda Morgan, John Litchfield, Andy Rawlins, Judy Waltz, Adam Schurle, Jennifer Urban and Jim Mckeown, Senior Counsel Eric Chow, and Associates Eric Lauria-Banta, Ethan Floyd, and Samuel D. Goldstick.